Collaborations & Alliances

OSE Immunotherapeutics, MAbSilico Enter AI Alliance

To leverage innovative problem-solving solutions like AI for the development of new monoclonal antibodies

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

OSE Immunotherapeutics has entered a collaboration agreement with technology start-up MAbSilico to use artificial intelligence (AI)-based solutions for therapeutic antibody drug development. OSE Immunotherapeutics plans to incorporate innovative problem-solving solutions like AI for the development of new monoclonal antibodies. MAbSilico solutions have been tested and validated by OSE and will be used for six antibody programs, including novel bispecific antibodies. Leveraging AI and numerica...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters